Data-driven

Kallyope Inc.’s data-intensive approach to mapping the gut-brain axis led Two Sigma Ventures to join the biotech’s $66 million series B round, marking the VC’s second investment in therapeutics.

Existing investor Lux Capital led the round, which closed on Feb. 22. Existing investors The Column Group, Polaris Partners, Illumina Ventures and Alexandria Venture Investments also participated alongside new investors Euclidean Capital and Two Sigma. ...